

FOR IMMEDIATE RELEASE

Sidney Dung
+39 0331 511380
Sidney.dung@nmsgroup.it

NerPharMa Appoints Claudio Salvagnini as Deputy CEO

Nerviano_2023-09-01_NerPharMa Srl (NerPharMa), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company's strategic direction and ensuring operational efficiency.

In this enhanced capacity, Claudio will also take on a more focused leadership role, dedicated to refining and optimizing the company's business operations, supply chain initiatives, project management strategies and developing client portfolio, leveraging his extensive experience and proven leadership. Also, he will spearhead initiatives aimed at streamlining processes, enhancing productivity, and fortifying relationships with our existing and new clients and long-term partners.

"Claudio has been a catalyst for innovation and progress within our organization," stated Hugues Dolgos, PharmaD, at NerPharMa. "The elevation of his role underscores our commitment to leverage his exceptional network and knowledge in the CDMO operations and customer needs, elevating and fortifying our position as a leading niche CDMO and CMO partner in the biotech and pharma industry."

Claudio expressed his enthusiasm for the new role, stating, "I am very excited to take on this new role in NerPharMa. I am committed to fostering operational excellence, driving innovation, and ensuring full satisfaction of our clients by further strengthening our support level, with customized supply chain and project management solutions, aligning with the evolving needs of our partners. The unique selling proposition of NerPharMa, offering fully integrated drug substance, drug product and final packaging of highly potent drugs from our Bio-Park in Nerviano (Milan, IT), provides already seamless support to global pharma companies from late discovery, through clinical development to commercialization stage across the whole product lifecycle. We will continue in building on decades of experiences on the field by focused investment in new technologies and capabilities to meet and exceed our customers' expectations. I am honored and proud to be part of this journey."

The company remains dedicated to advancing pharmaceutical and biotech manufacturing, and Claudio's elevated role underscores the company's commitment to meeting the evolving needs of our clients, nurturing and empowering its internal talent to lead critical functions.

###

About NerPharMa

NerPharMa owns a wide and cutting-edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products intended for the world market as well as the research and development of innovative formulation and delivery systems. The two divisions in NerPharMa, NerPharMa DS (drug substance) and NerPharMa DP (drug product), operate in accordance with Current Good Manufacturing Practices (cGMP) and are authorized by the most relevant authorities: Italian Drug Agency (AIFA), U.S. Food and Drug Administration (FDA), ANVISA Brazil, China FDA, PMDA Japan and Russia for the production of both pharmaceutical active ingredients and finished products.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

The NMS Group has three subsidiaries. NMS srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.